CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Lenalidomide +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02375555
NCT02375555Phase 2Completed
CompareCT.gov

An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma

Dana-Farber Cancer Institute·interventional·Posted Mar 2, 2015·Updated Oct 1, 2024

In Brief

A Phase 2 clinical trial evaluating Lenalidomide, Elotuzumab, and 3 other interventions for Multiple Myeloma. Completed, enrolled 40 participants across 7 sites.

Detailed Summary

This research study is evaluating a combination of four drugs -- lenalidomide, bortezomib, dexamethasone and elotuzumab -- as therapy for newly diagnosed multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2, 2015
Enrollment StartMay 7, 2015
Primary CompletionDec 15, 2021
Study CompletionJan 26, 2024
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 11.3 years ago

Interventions

Lenalidomidedrug

Elotuzumabdrug

Bortezomibdrug

Dexamethasonedrug

Stem Cell Mobilizationprocedure